Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Sponsor: Akiva Mintz
Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours
Official title: Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake
Key Details
Gender
All
Age Range
18 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-05-20
Completion Date
2030-06-30
Last Updated
2025-06-10
Healthy Volunteers
Yes
Conditions
Interventions
18F-Florbetapir or 18F-Flutemetamol
Participants will be injected with 18F-Florbetapir or 18F-Flutemetamol and imaged for up to 3 hours on a PET scanner
Locations (1)
Nuclear Imaging Institute
Englewood, New Jersey, United States